Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Raymond Cho, MD, PhD
Headshot of Raymond Cho
Raymond Cho

Description

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Details

This is a one-arm, open-label study to examine the effect of Tildrakizumab on cutaneous and blood immune cells of psoriatic patients. Ten subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for tildrakizumab-corrected signatures.

Keywords

Psoriasis Vulgaris, Psoriasis, Antibodies, Monoclonal, Tildrakizumab Prefilled Syringe

Eligibility

You can join if…

Open to people ages 18-75

  • 18 years of age or older
  • Patients with moderate-severe psoriasis or > 5% body surface area affected.

You CAN'T join if...

  • taking systemic immunosuppressives in the last 4 weeks
  • pregnancy
  • severe immunodeficiency (either from genetic or infectious causes).
  • tuberculosis or other active serious infection
  • active systemic malignancy.
  • breast-feeding
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Location

  • University of California, San Francisco
    San Francisco California 94115 United States

Lead Scientist at UCSF

  • Raymond Cho, MD, PhD
    Dr. Cho is a physician and geneticist who investigates the molecular basis of skin disease. With colleague Dr. Jeffrey Cheng, he co-leads the RashX initiative at UCSF, which develops high resolution molecular fingerprints to understand and treat unusual skin diseases.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05390515
Phase
Phase 4 Psoriasis Research Study
Study Type
Interventional
Participants
Expecting 10 study participants
Last Updated